NCT05160545View on ClinicalTrials.gov

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 26, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

GNC-035

Administration by intravenous infusion

Trial Locations (6)

510120

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

Unknown

The First Affiliated Hospital of Bengbu Medical College, Bengbu

Dongguan People's Hospital, Dongguan

ZhuJiang Hospital of Southern Medical University, Guangzhou

The Third Hospital of Changsha, Changsha

West China Hospital，Sichuan University, Chengdu

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY